Kintor Pharma Announces Completion of Phase I Clinical Trial of GT20029 in the US

(Summary description)

Kintor Pharma Announces Completion of Phase I Clinical Trial of GT20029 in the US

(Summary description)

Information
KX-826 Phase III Clinical Trial for Treatment of Male AGA in China Completed
KX-826 Phase III Long-term Safety Clinical Trial in China Completed Patient Enrollment
GT1708 Obtained Conditional Approval to Conduct Phase II Clinical Trial in China by NMPA for IPF
KX-826 Phase II Clinical Trial for Treatment of Male AGA in the U.S. Completed
GT1708 Phase I Clinical Trial for Treatment of Hematologic Malignancies in China Completed
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
Kintor Pharma Announces Completion of Phase I Clinical Trial of GT20029 in the US

Scan the QR code to read on your phone